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Background: Negative symptoms of psychosis do not respond to the traditional therapy with first- or second-
generation antipsychotics and are among main causes of a decrease in quality of life observed in individuals suffering
from the disorder. Minocycline, a broad-spectrum tetracyclic antibiotic displaying neuroprotective properties has been
suggested as a new potential therapy for negative symptoms. In the two previous clinical trials comparing minocycline
and placebo, both added to the standard care, patients receiving minocycline showed increased reduction in negative
symptoms. Three routes to neuroprotection by minocycline have been identified: neuroprotection against grey matter
loss, anti-inflammatory action and stabilisation of glutamate receptors. However, it is not yet certain what the extent of
the benefit of minocycline in psychosis is and what its mechanism is. We present a protocol for a multi-centre
double-blind randomised placebo-controlled clinical trial entitled The Benefit of Minocycline on Negative Symptoms of
Psychosis: Extent and Mechanism (BeneMin).
Methods: After providing informed consent, 226 participants in the early phase of psychosis will be randomised to
receive either 100 mg modified-release capsules of minocycline or similar capsules with placebo for 12 months in
addition to standard care. The participants will be tested for outcome variables before and after the intervention period.
The extent of benefit will be tested via clinical outcome measures, namely the Positive and Negative Syndrome Scale
score, social and cognitive functioning scores, antipsychotic medication dose equivalent and level of weight gain. The
mechanism of action of minocycline will be tested via blood screening for circulating cytokines and magnetic
resonance imaging with three-dimensional T1-weighted rapid gradient-echo, proton density T2-weighted dual
echo and T2*-weighted gradient echo planar imaging with N-back task and resting state. Eight research centres
in UK and 15 National Health Service Trusts and Health Boards will be involved in recruiting participants, performing
the study and analysing the data.
Discussion: The BeneMin trial can inform as to whether in minocycline we have found a new and effective therapy
against negative symptoms of psychosis.
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The European Union Clinical Trial Register: EudraCT 2010-022463-35 with the registration finalised in July 2011. The
recruitment in the trial started in January 2013 with the first patient recruited in March 2013.
Keywords: Minocycline, Psychosis, Negative symptoms, Neuroprotection, Double-blind randomised placebo-
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Magnetic resonance imagingBackground
Negative symptoms in psychosis
Psychosis leads to a significant decrease in a person’s
quality of life [1], with negative symptoms contributing
the most to impaired functional outcome [2]. Negative
symptoms - reduction in emotional and social responsive-
ness, motivation, speech and movement [3] - respond the
least to known antipsychotic treatments among all psych-
otic symptoms [4]. Their initial severity, together with
duration of untreated psychosis (DUP) and cognitive im-
pairments, is the best predictor of an individual’s subse-
quent impairment in quality of social and occupational
functioning [5]. Their positive correlation with DUP links
their aetiology to a neuropathic process progressing with
continuance of untreated psychosis [6-11]. This hypoth-
esis has led to an interest in neuroprotection during early
stages of psychosis as a potential therapeutic target for
negative symptoms.Efficacy of minocycline for negative symptoms of
psychosis
A broad-spectrum tetracyclic antibiotic, minocycline has
neuroprotective properties, which could prevent the
accumulation of negative symptoms in psychosis [12-15]
while improving the prognosis of neurodegenerative
diseases and traumatic or ischaemic central nervous system
(CNS) insults [16-19]. Due to its lipophilic properties, it has
exceptional potential for blood-brain barrier penetration
[20]. It is also marked by its relatively low toxicity [21].
Two double-blind randomised placebo-controlled stud-
ies of minocycline as a neuroprotective agent for negative
symptoms of psychosis have been completed [14,15].
The first was a 2-centre study in Brazil and Pakistan su-
pervised by the University of Manchester with 144 par-
ticipants [14]. The second, completed in Tel Aviv,
Israel, recruited 70 relapsed patients with schizophrenia
[15]. Both studies found significant treatment effects on
negative symptoms with adjunctive minocycline. In the
first trial, significant treatment effects were observed at
6 months, and in the second trial at 3 months. Further-
more, the 2-centre trial demonstrated that therapeutic
effects were sustained at 12 months. No other trials in-
vestigating the efficacy of minocycline for negative
symptoms have been registered in UK or US databases.
However, to assess the extent and mechanism of thebenefit of minocycline for negative symptoms in psych-
osis, a trial with a larger cohort is needed.Mechanism of action of minocycline on negative
symptoms
Although the effectiveness of minocycline in treating
negative symptoms has been identified, its mechanism of
action remains unresolved [22]. Three possible mecha-
nisms of action have been posited:
1) Neuroprotection against grey matter loss: minocycline
may directly prevent neurodegeneration of grey matter
in individuals with psychosis. Its neuroprotective
properties have been shown in stroke [21,23],
Parkinson’s disease [24,25], cerebral ischaemia,
amyotrophic lateral sclerosis, Huntington’s disease and
multiple sclerosis [26]. In psychosis, loss of grey matter
occurs early in the course of the disease [27-30], is
associated with DUP [31] and predicts diminished
functional outcome [32]. By preventing grey matter
loss, minocycline may limit negative symptoms.
2) Anti-inflammatory action: the anti-inflammatory
properties [33,34] of minocycline may prevent neural
changes associated with the action of microglia and
cytokines in psychosis [35]. The inflammatory
response as a mechanism of schizophrenia has been
suggested by studies demonstrating microglial
activation [35,36]. The gene variants associated with
risk of schizophrenia have been linked to increased
levels of circulating cytokines [37]. A correlation
between negative symptoms and levels of IL-10
cytokine has been observed in untreated psychosis
[38]. Increased levels of IL-6 appears in medication-
naïve patients with first episode of psychosis [39]
and acutely relapsed inpatients [40], whereas
elevated levels of IL-6 at the age of 9 doubles the
risk of developing psychosis later in life [41].
Minocycline may reduce cytokine levels during
psychosis thereby limiting negative symptoms.
3) Stabilisation of N-methyl-D-aspartate (NMDA)
glutamate receptors: minocycline may improve
impaired function of the NMDA glutamate receptor
which is thought to display impairment in
schizophrenia [42]. Ketamine, which blocks NMDA
receptors and causes dysfunctional release of
Lisiecka et al. Trials  (2015) 16:71 Page 3 of 15glutamate [43,44], evokes schizophrenia-like negative
symptoms in healthy individuals [45]. Minocycline can
block ketamine action [46], thus potentially stabilising
glutamate release in NMDA receptors [47].
Minocycline may limit negative symptoms either
through direct action on glutamate release or through
prevention of glutamate neurotoxicity on neuronal
branching and glial cells [48]. Although not observable
in vivo, this can be examined by the association be-
tween NMDA receptors and working memory [49,50].
The three mechanisms of action of minocycline may
operate separately or jointly. Each represents a potential
target for neuroprotectection, effective only when neuro-
degenerative processes are active and their adverse effects
limitable. Thus, minocycline is likely to be observed as be-
ing most effective in the early stages of psychosis.
Benefits and risks of treatment with minocycline
The treatment of psychosis with minocycline may bene-
fit patients by reducing their negative symptoms and,
consequently, their difficulties in social and occupational
function [5]. This treatment may also reduce the dose of
antipsychotic drugs (APDs) necessary to stabilise a pa-
tient’s health, thus decreasing potential side-effects of
APDs such as weight gain [4]. Finally, new targets for the
treatment of psychosis may be discovered [51], which
could elucidate the pathophysiology of psychosis and po-
tential biomarkers of increased risk of developing it.
Treatment with minocycline has been associated with
vestibular disturbances, gastro-intestinal upset and
fatigue [52-54]. Nevertheless, our previous study [14] did
not find any such link. Minocycline use has also been
associated with the development of a systemic lupus
erythematosus - like syndrome [55] with, however, an
estimated incidence of 8.8 cases per 100,000 person-years
[56]. Patches of discolouration on teeth and skin have also
been observed during long-term therapy with minocycline
[57,58]. In our previous study [14], three people in each
treatment arm reported hyper-pigmentation, but only those
in the minocycline arm withdrew from the trial. This was
the only noted side-effect withdrawal.
The risks and side-effects observed during minocycline
treatment are less severe than those associated with the
available antipsychotic drugs, which include extrapyram-
idal symptoms [59-61], metabolic problems and sedation
[62-68]. It is estimated that adding minocycline to stand-
ard treatment will have similar effect-size as was ob-
served with a benefit of second-generation APDs over
older APDs [62,69].
Rationale and aims of the BeneMin trial
Finding an effective treatment for negative symptoms in
psychosis is of paramount importance due to their rolein post-morbid functional outcome [2]. Minocycline has
been identified as a potential agent for reducing negative
symptoms [14,15]. Therefore, in BeneMin we will inves-
tigate the extent and mechanism of action of minocy-
cline on negative symptoms in psychosis. Additionally,
we will test whether characteristics such as premorbid
and current IQ, DUP and cytokine genotype predict the
response to minocycline.
Effectiveness hypotheses (EHs)
EH1) Added to the standard therapy, minocycline
administered during the acute phase of psychosis limits
development of negative symptoms in comparison to
placebo.
EH2) Minocycline reduces side-effects associated with
standard therapy such as weight gain in comparison to
placebo.
EH3) Reduction of negative symptoms leads to
improvement in function and life quality in patients
treated with minocycline in comparison to placebo.
Mechanistic hypotheses (MHs)
MH1) In comparison to placebo, minocycline reduces
grey matter degeneration, which occurs particularly
during the early acute phase of the disease. The
reduction in grey matter degeneration is observed
mainly in the frontal lobes and is associated with
reduction of negative symptoms.
MH2) In comparison to placebo, minocycline
diminishes inflammatory action in the CNS thereby
reducing negative symptoms. Decreased numbers of
circulating cytokines in peripheral blood, and
potentially reduced grey and white matter
neurodegeneration and micro lesions in the CNS, are
observed as the result of minocycline treatment.
MH3) In comparison to placebo, minocycline improves
function of NMDA glutamate receptors and restores
optimal levels of glutamate in the CNS, observed
through improved cortical function of working
memory. The improvement may be a direct result of
minocycline action and may cease after the treatment
stops or continue through the neuroprotective action
of optimal glutamate levels.
Methods
Study design
BeneMin is a double-blind, randomised, placebo-controlled
clinical trial investigating the extent and mechanism of
action of minocycline on negative symptoms of psych-
osis in addition to standard APD therapy. Participants
in an acute psychotic phase will be randomly allocated
either to the minocycline or to the placebo arm and
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Both participants and investigators will be blind to treat-
ment group, which will be guaranteed by a direct data-
entry, digital database (OpenCDMS system). Separately,
participants will be asked to donate fully-anonymised
DNA for genotyping of the interleukin 6 (IL-6) gene [70]
and for future investigations. The study will be conducted
at eight research centres, and led by the University of
Manchester (Table 1).
The EHs will be tested via clinical outcome variables:
levels of negative and positive symptoms of psychosis,
observed side-effects and subsequent quality of life. The
MHs will be examined via biomarker outcome variables
obtained through blood screening for circulating cytokines
and magnetic resonance imaging (MRI). In addition to
treatment effectiveness, mediators of treatment response
such as DUP, cognitive function and IL-6 gene variants
will be assessed.
A pre-post treatment design will be used with baseline
measurements of the outcome variables taken before
commencement of treatment (screening and randomisa-
tion visits) and repeated soon after the treatment has
finished (month 12 visit). Clinical outcome variables will
also be measured between the pre- and post-treatment
assessments (month 2, 6 and 9 visits) to capture pos-
sible early therapeutic effects of minocycline. The lastTable 1 Research centres involved in BeneMin with the corres
Boards and magnetic resonance imaging (MRI) centres
Research centres NHS trusts and health b
University of Manchester • Manchester Mental Heal
• Greater Manchester Wes
Foundation Trust
• Pennine Care NHS Foun
Lancashire Early Intervention Services • Lancashire Care NHS Fo
Cheshire and Wirral Partnership Early Intervention
in Psychosis Service
• Cheshire and Wirral Part
Trust
University of Cambridge • Cambridge and Peterbo
Trust
• Norfolk and Suffolk NHS
University College London • West London Mental He
• Central and North West
Trust
• Camden and Islington N
• Barnet, Enfield and Harin
King’s College London • South London and Mau
Trust
University of Edinburgh • NHS Lothian
• NHS Fife (PIC)
University of Birmingham • Birmingham and Solihul
Foundation Trust
PIC, patient identification centre.assessment will be performed 3 months after the par-
ticipant has finished their treatment (that is 15 months
post-randomisation).
Participants
Eligibility criteria
The BeneMin trial will recruit participants in an acute
phase of psychosis within 5 years from their first diagno-
sis. The detailed inclusion and exclusion criteria of the
participants are presented in Figure 1.
Sample size and recruitment settings
We aim to enrol a total of 226 eligible participants
among the 8 research centres. The predicted number of
participants remaining in the trial at each stage is pre-
sented in the CONSORT diagram in Figure 2. The calcu-
lations are based on our previous study of minocycline
[14] and a calibration study we performed before this
trial [71]. The number of participants was chosen to
ensure feasibility of the analysis of post-treatment MRI
scans. To meet our recruitment aims we will collabor-
ate with Local Research Networks of the English
National Institute for Health Research and Scottish
Mental Research Networks. The patients will be re-
cruited via 15 National Health Service (NHS) Trusts
and Health Boards (Table 1).ponding National Health Service (NHS) Trusts, Health
oards MRI centres
th and Social Care Trust MRI facility in Salford Royal NHS Foundation
Trust
t Mental Health NHS
dation Trust (PIC)
undation Trust
nership NHS Foundation
rough NHS Foundation Wolfson Brain Imaging Centre Cambridge
Foundation Trust (PIC)
alth NHS Trust Wellcome Trust Centre for Neuroimaging
University College London
London NHS Foundation
HS Foundation Trust
gey Mental Health Trust
dsley NHS Foundation Centre for Neuroimaging Sciences King’s
College London
Clinical Research Imaging Centre Edinburgh
l Mental Health NHS Birmingham University Imaging Centre
Figure 1 Eligibility and withdrawal criteria for participants of BeneMin.
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gated members of their clinical teams, who will assess
each candidate’s eligibility and ask for their permission
to be contacted by a project’s research assistant (RA).
Eligible candidates will receive the BeneMin patient in-
formation leaflet explaining the trial. After expressing
interest they will be approached by the RA who will
again verify eligibility. Subsequently, the RA will obtain
the candidate’s informed consent for participation in the
trial, having verified that the candidate fully understands
what is involved. Separate consent will be obtained fordonating DNA to the bio-bank at the University of
Manchester.
Withdrawal
At any time a participant can withdraw their consent for
participation without giving reasons. The participant will
be given an opportunity to discuss the reason for with-
drawal and any adverse events (AE). If possible, the
participant will be assessed by the investigator. Any
potential AE will be followed up by the resident medical
officer (RMO). If the participant withdraws their consent
Figure 2 CONSORT diagram with predicted numbers of
participants at each stage of the trial.
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asked to complete the full post-treatment assessment,
followed 3 months later by the post-trial assessment.
Their results will be included in the main analysis. The
detailed withdrawal criteria are presented in Figure 1.
Randomisation procedure
After stratification by the research centre, permuted
block randomisation integrated with the OpenCDMS
system will be used to allocate participants to thetreatment arm. After an investigator has requested ran-
domisation for a participant, the OpenCDMS will use
the algorithm to allocate the participant to the treatment
arm. Subsequently, it will notify a local pharmacy re-
garding the serial number of a medication kit to use.
Participant’s allocation to the study arm will be known
only to the OpenCDMS system.
Planned intervention
Participants will take capsules containing either 100 mg
minocycline (modified-release) or matching placebo, 2
per day for the first 2 weeks and then 3 per day for the
reminder of the 12-month treatment period in addition
to standard therapy. The maximum dose of modified-
release minocycline is 3 × 100 mg per 24 hours. Mino-
cycline and placebo will be manufactured, controlled
and distributed to the Trusts’ pharmacies by Catalent,
Bolton, UK, in accordance with the requirements of the
Medicines and Healthcare Products Regulatory Agency
(MHRA).
Clinical outcome measures
We will test hypotheses of minocycline efficacy by asses-
sing changes in primary and secondary clinical outcome
measures over treatment.
Primary clinical outcome
Severity of negative symptoms of psychosis as measured
by the negative symptoms subscale of the Positive and
Negative Syndrome Scale (PANSS), an instrument com-
monly used to assess the efficacy of treatment in schizo-
phrenia [72] consisting of a positive symptoms subscale,
a negative symptoms subscale and a general psychopath-
ology subscale [73].
Secondary clinical outcomes
1) Body weight and body mass index [74] as a measure
of weight gain, a side-effect of the standard APD
therapy.
2) Severity of global and positive symptoms of
psychosis as measured by the full PANSS and the
PANSS positive symptoms subscale.
3) General and social function as measured by:
 Global Assessment of Functioning from the
Diagnostic and Statistical Manual, fourth edition
(DSM-IV) [75,76], a scale assessing psychological,
social and occupational function on a
hypothetical continuum of health and illness;
 the Social Functioning Scale [77], a self-rating
scale assessing social functioning in domains such
as social engagement, interpersonal behaviour,
pro-social activities, independence or
employment.
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 a short Wechsler Adult Intelligence Scale III for
patients with schizophrenia [78], consisting of the
information, block design, arithmetic and digit-
symbol subtests. This will provide a measure of
current IQ and processing speed [79];
 the Wechsler Test of Adult Reading [80], a
reading test which estimates premorbid IQ [81];
 Verbal fluency requiring individuals to generate
words in response to phonetic or semantic
criteria [82];
 the Auditory-Verbal Learning Task [83-85], a test
of word list learning and recall.
5) APD dose expressed in chlorpromazine equivalent
units [86], assessing the dose of APD required for
the patient’s stabilisation.
Biomarker outcome measures
We will examine the mechanism of action of minocycline
by assessing changes in primary and secondary biomarker
outcome measures over treatment. The biomarker out-
comes will be measured via cytokine blood screening and
MRI of the brain.
Cytokine blood screening
A blood sample from the participant will be collected
into an EDTA tube during a screening visit. Portions of
plasma will be separated from the sample for measure-
ment of the cytokine markers associated with inflamma-
tory response in previous studies, namely, IL-6 [87],
interleukin-1 receptor antagonist (IL-1RA) [88], mono-
cyte chemotactic protein 1 (MCP-1/CCL2) [89] and
C-reactive protein (CRP) [90]. Measurements of IL-6,
IL-1RA and MCP-1 will follow a method applied in pre-
vious studies of stroke [91,92] and will use multiplex
(Luminex®, Manchester, UK) assays. For assessment of
CRP level, a sensitive immunoassay will be used [93].
The lowest value among the markers will be classified as
the baseline measure of cytokine concentration. Succes-
sive blood samples will be collected, and the cytokine
tests repeated at month 6, post-treatment (month 12)
and post-trial (month 15) visits.
Multi-centre magnetic resonance imaging
Three MRI sequences will be performed for each par-
ticipant pre-treatment (randomisation visit) and post-
treatment (12 month visit): three-dimensional T1-weighted
rapid gradient-echo (MPRAGE/SPGR); proton density
T2-weighted dual echo (PD/T2); and T2*-weighted gra-
dient echo planar imaging (EPI) with N-back task and
resting state. MPRAGE/SPGR, a high-resolution struc-
tural scan, will be used to assess volume and, thus,
neurodegeneration of grey matter. PD/T2 will measure
the volume of grey and white matter and of neuro-inflammatory lesions, and will be applied to perform
multi-channel texture analysis [94], thus supporting the
measurements of neuro-inflammation. EPI N-back via
blood-oxygenation-level-dependent (BOLD) contrast will
be used to test the neural function associated with the
working memory network (dorsolateral-prefrontal, an-
terior cingulate and parietal cortices) [95] and, thus,
NMDA receptors [49,50], whereas EPI resting state will
be applied to observe the default network (medial tem-
poral, medial prefrontal and posterior cingulate corti-
ces) [96,97]. Both sequences will be used to examine
functional connectivity, and be merged at acquisition
into one sequence to test endogenous neural dynamics
recovery from cognitive effort [98].
N-back task In the N-back task, a well-established
method for observing the working memory network
[99], the participant presses a button corresponding to
the number observed N images previously. The numbers
will range from 1 to 4 and the participant will hold a 4-
button response box in their right hand. The task will
consist of 3 types of blocks, 0-back, 1-back, 2-back, each
repeated 5 times in quasi-randomised fashion (the same
randomised pattern for each participant). Each block will
contain an instruction image (3,750 ms) followed by 15
quasi-randomised trials comprising an image presenting
the number (250 ms) and a blank image (1,500 ms)
(Figure 3). The response can be given when either the
number or the blank image are presented. Reaction
times and response accuracy are recorded. After the task
has finished an image will appear instructing the partici-
pant to close their eyes for the remaining part of the
sequence.
Multi-centre MRI reproducibility Multi-centre im-
aging studies are an effective way to reach a target
sample size in a clinical trial within a manageable
time-frame. However, due to technical and setting
differences between MRI scanners, the question of
reproducibility and comparability of data arises. In
BeneMin the MRI data will be collected in six MRI
centres (Table 1) via six 3T MRI scanners, including
two Philips Achieva (Philips Medical Systems, Best,
Netherlands), two Siemens Trim Trio, one Siemens
Verio (Siemens Medical Systems, Erlangen, Germany)
and one GE Signa (General Electric, Milwaukee, WI,
USA). Due to technical differences between scanners,
a direct replication of scanning parameters would not
result in functionally equivalent MRI protocols.
Therefore, to develop BeneMin MRI protocols we
have applied expertise established by the Alzheimer’s
disease neuroimaging initiative (ADNI) [100], a multi-
centre imaging project aiming at standardisation of MRI
across sites and manufacturers, and conducted a
Figure 3 N-back task and resting state diagram.
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study, in which 12 healthy volunteers were scanned re-
peatedly in 5 different MRI centres with a protocol similar
to ours, showed that between-centre differences
accounted for 10% of variation in structural MRI and less
than 10% in functional MRI, whereas centre-by-individual
interaction was on the level of < 5%. In BeneMin the speci-
fications for each sequence are:
1) MPRAGE/SPGR: voxel size of approximately 1 × 1 ×
1 mm3, phase encode on the anterior-posterior
plane, whole brain recorded;
2) PD/T2: voxel size of approximately 1 × 1 × 3 mm3,
phase encode on the right-left plane, whole brain
recorded;
3) EPI: TR = 2,000 ms, 748 three-dimensional
volumes, voxel size of approximately 3 × 3 ×
4.5 mm3, slices aligned to AC-PC axis, phase
encode on the anterior-posterior plane, whole
brain recorded.
These parameters have been fixed as their variations
cannot easily be compensated during analysis. After
these specifications were incorporated, each MRI
centre developed the remaining parameters of the
local BeneMin MRI sequences based on standardised
protocols of ADNI complemented by the centre’s
expertise. The protocols thus developed will be used
in BeneMin, and are presented in Table 2.Primary biomarker outcomes
1) Medical prefrontal grey matter volume (MH1).
2) Circulating cytokine IL-6 concentration (MH2).
3) Dorsolateral-prefrontal cortex BOLD response,
accuracy and functional connectivity in N-back task
(MH3).
Secondary biomarker outcomes
1) Total and other regional grey matter volumes (MH1).
2) Volume and multi-channel features of grey and
white matter as measured by PD/T2 and of
neuro-inflammatory lesions, and concentration of
the remaining cytokine markers (MH2).
3) Functional connectivity and the distribution of
Hurst exponent of fMRI noise in resting state
(MH3).
Side-effects and adverse events
Possible side-effects and potential co-morbidities will
be recorded. Depression will be assessed with self-
rating Calgary Depression Scale for Schizophrenia [101],
extrapyramidal symptoms with the Simpson-Angus Scale
[102], the Barnes Akathisia Rating Scale [103], the Abnor-
mal Involuntary Movements Scale [104] and APD subject-
ive side-effects with the Antipsychotic Non-Neurological
Side-Effects Rating Scale [105]. The seven-point ad-
herence to treatment scale will be also used [106].
Table 2 Reproducibility and comparability of local BeneMin magnetic resonance imaging (MRI) protocols and N-back
presentation
Wolfson Brain
Imaging Centre
Cambridge
MRI facility in
Salford Royal NHS
Foundation Trust
Wellcome Trust
Centre for
Neuroimaging UCL
Centre for
Neuroimaging
Sciences KCL
Clinical Research
Imaging Centre
Edinburgh
Birmingham
University
Imaging Centre
MRI scanner Siemens Trim
Trio
Philips Achieva Siemens Trim Trio GE Siemens Verio Philips Archieva
Field strength (Tesla) 3 T 3 T 3 T 3 T 3 T 3 T
Head Coil 12-channel 8-channel 12-channel 12-channel 12-channel 8-channel
MPRAGE/SPGR time 9:14 10:52 9:14 10:19 9:14 10:52
PD/T2 time 5:08 5:33 5:08 4:49 5:08 5:33
EPI time 25:02 25:04 25:00 25:04 25:02 25:08
MPRAGE/SPGR voxel size
FH/IS (mm)
1 1 1 1 1 1
MPRAGE/SPGR voxel size
AP (mm)
1 1 1 1 1 1
MPRAGE/SPGR voxel size
RL (mm)
1 1.2 1.2 1.2 1.2 1.2
PD/T2 voxel size AP (mm) 0.9 0.9 0.9 0.9 0.9 0.9
PD/T2 voxel size RL (mm) 0.9 0.9 0.9 0.9 0.9 0.9
PD/T2 voxel size FH/IS (mm) 3 3 3 3 3 3
EPI voxel size RL (mm) 3 3 3 3.3 3.4 3
EPI voxel size AP (mm) 3 3 3 3.3 3.4 3
EPI voxel size FH/IS (mm) 4.5 4.5 4.5 4.5 4 4.5
FOV MPRAGE/SPGR FH/IS (mm) 256 256 256 260 256 256
FOV MPRAGE/SPGR AP (mm) 256 (240) 256 (240) 256 (240) 260 256 (240) 240
FOV MPRAGE/SPGR RL (mm) 192 204 192 204 176 204
FOV PD/T2 AP (mm) 240 240 240 240 240 240
FOV PD/T2 RL (mm) 240 (214) 240 (210) 240 (214) 240 240 (214) 210
FOV PD/T2 FH/IS (mm) 144 144 144 144 144 144
FOV EPI RL (mm) 192 192 192 211 220 192
FOV EPI AP (mm) 192 192 192 211 220 192
FOV EPI FH/IS (mm) 126 175.5 126 126 129 175.5
Slice plane MPRAGE/SPGR Sagittal Sagittal Sagittal Sagittal Sagittal Sagittal
Slice plane PD/T2 Transverse Transverse Transverse Transverse/
axial
Transverse Transverse
Slice plane EPI Transverse Transverse Transverse Transverse/
axial
Transverse
> C-19.8 > S0.8
Transverse
EPI acquisition Interleaved Interleaved Interleaved Interleaved Interleaved Interleaved
Number of slices for
MPRAGE/SPGR
176 170 160 170 160 170
Number of slices for PD/T2 48 48 48 48 48 48
Number of slices for EPI 28 39 28 28 26 39
Number of volumes for EPI 748 748 748 748 748 748
Fold-over/phase encoding
direction MPRAGE/SPGR
A > > P A > > P A > > P P > > A A > > P A > > P
Fold-over/phase encoding
direction PD/T2
R > > L R > > L R > > L L > > R R > > L R > > L
Fold-over/phase encoding
direction EPI
A > > P A > > P A > > P P > > A A > > P A > > P
TE MPRAGE/SPGR (ms) 2.98 Shortest (3.1) 2.91 Min Full 2.98 3.1
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Table 2 Reproducibility and comparability of local BeneMin magnetic resonance imaging (MRI) protocols and N-back
presentation (Continued)
TR PD/T2 (ms) 3,000 3,000 3,000 3,000 3,000 3,000
TE 1 PD/T2 (ms) 11 Shortest (10) 11 Min Full 11 Shortest (10)
TE 2 PD/T2 (ms) 99 96 99 97.2 101 96
TR EPI (ms) 2,000 2,000 2,000 2,000 2,000 2,000
TE EPI (ms) 30 30 30 30 26 30
Flip angle MPRAGE/SPGR (deg) 9 8 9 8 9 8
Flip angle EPI (deg) 90 79 90 90 66 79
Distance factor for EPI (%) 0 0 0 0 25 (1 mm) 0
MRI data format DICOM DICOM DICOM DICOM DICOM DICOM
N-back task software Visual studio E-Prime 2.0.10 E-Prime 2.0.10 E-Prime 2.0.10
Professional
E-Prime 2.0.10 E-Prime 2.0.10
Professional
Response pad 4-button right
handed
4-button right
handed
4-button right
handed
4-button right
handed
4-button right
handed
5-button right
handed
Response box connection Parallel port USB USB USB USB USB
TTL pulses box connection Parallel port USB USB USB USB Parallel port
N-back data format TXT TXT TXT TXT TXT TXT
NHS, National Health Service; UCL, University College London; KCL, King’s College London; GE, General Electric; FH/IS, foot-to-head/inferior-to-superior;
AP, anterior-to-posterior; RL, right-to-left; FOV, field of view; A > > P, from anterior to posterior; P > > A, from posterior to anterior; R > > L, from right to left;
L > > R, – from left to right; TE, echo time; TR, repetition time; TTL, transistor-transistor logic.
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able medical condition or deterioration of an existing
medical concern will be recorded throughout the treat-
ment duration and the post-trial period.Assessment schedule
Each participant will undergo seven assessment sessions,
which will include the screening, the pre- and post-
treatment assessments, and the sessions between onset
and completion of treatment. The detailed measurements
taken during each session are presented in Table 3.Analysis
Statistical analysis
A single round of analysis will be undertaken after all out-
come results have been collected. Treatment effects will
be assessed using the intention-to-treat method unless a
significant amount of non-adherence to treatment is ob-
served, in which case the complier-average causal effect
method will be applied. In both cases non-adherence will
be accounted for, since both methods allow for missing
data via either inverse probability weights [107,108] or
maximum likelihood estimation [109,110], and non-
adherence is likely to correlate with withdrawals. Group
differences in outcomes and mediators of treatment re-
sponse will be assessed via a random effects model for
longitudinal data, whereas MHs will be tested with in-
strumental variable methods [111].MRI analysis
All MRI scans will be visually inspected for quality and
possible acquisition artefacts. Subsequently, each scan
will undergo standardised modality-specific temporal
and spatial pre-processing:
1) MPRAGE/SPGR and PD/T2: brain tissue extraction,
segmentation via scan-specific tissue priors, non-
linear registration to the Montreal Neurological
Institute 152 (MNI) standard space [112], smoothing
with an isotropic Gaussian kernel;
2) EPI: motion and slice-timing correction, brain tissue
extraction, non-linear co-registration with MNI-
registered MPRAGE/SPGR, smoothing with an
isotropic Gaussian kernel, intensity normalisation,
high pass temporal filter.
For both MPRAGE/SPGR and PD/T2, voxel-based
morphometry analysis will be performed [113], with
additional lesion count in PD/T2 [114]. Texture features
identified as neuro-inflammation markers in multiple
sclerosis [94] will be measured in PD/T2. In EPI a gen-
eral linear model will be used to model the BOLD signal
[115]. Additionally, for the EPI resting state, the Hurst
exponent will be extracted [116]. Group comparisons for
all measures will be performed for the whole brain and
for the regions of interest defined as belonging to posi-
tive and negative task networks [95-97] and located via
MNI Atlases [117]. A mixed effects model for repeated
measures will be used to evaluate treatment effectiveness
Table 3 Purpose and schedule of assessments in BeneMin
Screening Randomisation
(Pre-treatment)
Month
2
Month
6
Month
9
Month 12
(Post-treatment)
Month 15
(Post-trial)
Inclusion and exclusion criteria checklist EM
Case-note diagnostic checklist EM
Diagnostic and eligibility checklist EM and
CO
CO
Mini-International Neuropsychiatric Interview EM and
CO
CO
Positive and Negative Syndrome Scale EM and
CO
CO CO CO CO CO CO
Wechsler Adult Intelligence Scale III; 4 subtest short
form
EM and
CO
CO CO
Wechsler Test of Adult Reading EM and
CO
Verbal fluency EM and
CO
CO CO
Auditory-Verbal Learning Task EM and
CO
CO CO
Medication treatment history EM and
CO
CO CO CO CO CO CO
Pregnancy urine dipstick test EM WCM WCM WCM WCM WCM
Drug urine screening test EM WCM
Drug use questionnaire EM WCM WCM WCM WCM WCM SCo
Blood laboratory screening for kidney and liver
function
EM WCM
Blood pressure and heart rate EM WCM SCo
MRI screening questionnaire EM
Duration of untreated psychosis RP
Body weight and body mass index CO CO CO
Global Assessment of Functioning CO CO CO CO CO CO
Social Functioning Scale CO CO CO CO
MRI scanning BO BO
Blood cytokine screen test BO BO BO BO
Saliva Oragene kit for DNA donation RP
Withdrawal criteria checklist WCM WCM WCM WCM WCM
Calgary Depression Scale for Schizophrenia SCo SCo SCo SCo SCo SCo
Simpson and Angus Scale SCo SCo SCo SCo
Barnes Akathisia Scale SCo SCo SCo SCo
Abnormal Involuntary Movements Scale SCo SCo SCo SCo
Antipsychotic Non-Neurological Side-Effects Rating
Scale
SCo SCo SCo SCo SCo SCo
7-point compliance scale AT AT AT AT
EM, eligibility measure; CO, clinical outcome; RP, response predictor; BO, biomarker outcome; WCM, withdrawal criteria measure; SCo, side-effects and co-morbidity;
AT, adherence to treatment.
Intersections between lines and columns show if the test took place during the visit (cells containing an abbreviation). Abbreviations explicate the reason why the
test was performed at a particular stage of the trial and how the particular measure fits into statistical design of the study.
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Additionally, a partial least squares model will be applied
to identify brain structures and activation patterns associ-
ated with the extent of symptomatic change. Furthermore,seed-based correlations of voxel time-series will be used
in EPI to establish treatment effects on functional con-
nectivity of the positive and negative task networks [118].
All MRI analyses will be performed via non-parametric
Lisiecka et al. Trials  (2015) 16:71 Page 12 of 15testing, with appropriate corrections for multiple com-
parisons [119].
Ethics approval and research sponsor
The study design and the described procedures have been
approved by the National Research Ethics Service Com-
mittee North West - Greater Manchester Central (REC
reference number: 11/NW/0218). The following local Re-
search and Development departments of NHS Trusts and
Health Boards after being presented with the aforemen-
tioned approval agreed to host the study: the Manchester
Mental Health and Social Care Trust Research and
Innovation Office, the Greater Manchester West Mental
Health NHS Foundation Trust Research and Develop-
ment Office, the Pennine Care NHS Foundation Trust
Quality Assurance, Research and Innovation Unit, the
Lancashire Care NHS Foundation Trust Research Depart-
ment, the Cheshire and Wirral Partnership NHS Foun-
dation Trust Academic Unit, the Cambridgeshire and
Peterborough NHS Foundation Trust Research and De-
velopment Department, the Norfolk and Suffolk NHS
Foundation Trust Research and Development Office,
the UCL/UCLH Joint Research Office, the North Central
London Research Consortium, the South London and
Maudsley/IoPPN Research and Development Office, the
NHS Lothian Academic and Clinical Central Office for
Research and Development, the NHS Fife Research and
Development Resource Centre and the Birmingham and
Solihull Mental Health Foundation NHS Trust Research
and Development Department. The Manchester Mental
Health and Social Care Trust is the research sponsor and
will be responsible for monitoring, audit and pharmacov-
igilance of the trial. The trial has the approval of MHRA.
Discussion
Minocycline has the potential to improve the treatment
of negative symptoms in psychosis and thereby protect
premorbid levels of functioning and consequently the
quality of life for many patients. The medication has low
toxicity and is not expensive to manufacture, hence it
could be a straightforward addition to standard care.
Furthermore, minocycline may reduce the dose of anti-
psychotic drugs necessary to stabilise a patient’s condi-
tion and thus limit side-effects associated with standard
antipsychotic therapy.
Therapy with minocycline can potentially prevent ir-
reparable neurodegenerative changes observed in the
early stages of psychosis, which are proposed as a cause
of negative symptoms. If the mechanism of action of
minocycline is revealed, new targets for therapy of
psychosis will be established and novel medications with
clinical properties associated with the mechanism may
be developed. Discovering the mechanism could also
elucidate a neural basis of psychosis itself.BeneMin as a multi-site clinical trial will evaluate the
extent and mechanism of efficacy of minocycline for
negative symptoms in a manageable time-frame. How-
ever, the multi-site character of BeneMin raises an issue
of reproducibility and comparability of the data. There-
fore, standardisation of procedures such as MRI and
compatible training for the data collectors will be of key
importance. On the other hand, recruiting participants
from many geographical locations increases ecological
validity of the sample which in turn helps with general-
isation of the findings.
Trial status
The trial is ongoing. Participants are currently being
recruited.
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